Outcome of Board Meeting

October 28, 2026 The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/ Madam, Trading Symbol: ZOTA Sub: Outcome of Board Meeting held on Wednesday, October 28, 2026 Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject; we, M/s Zota Health Care Limited (the “Company”), would like to inform you that the Board of Directors of the Company in its Meeting held on Wednesday, October 28, 2026 at 02:00 P.M. at Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have inter alia, discussed and approved the following business: 1. Considered and approved Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended on September 30, 2026 along with the Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (Annexure-1). Unaudited Standalone and Consolidated Financial Results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.com and on Company’s website at www.zotahealthcare.com. The Board meeting concluded at 4:15 P.M. This is for your information and record. Thanking you, Yours faithfully, For Zota Health Care Limited Ashvin Variya (Group Company Secretary & Compliance Officer) Place: Surat Encl.: a/a Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352 Pradeep K Singhi & Associates CHARTERED ACCOUNTANTS Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors of Zota Health Care Limited We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Zota Health Care Limited (the “Company”) for the quarter and half year ended September 30, 2026 (“the Statement”) attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. Management’s Responsibility This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. Auditor’s Responsibility We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Conclusion Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001 PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com Pradeep K Singhi & Associates CHARTERED ACCOUNTANTS Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For Pradeep K. Singhi & Associates Chartered Accountants FRN : 0126027W Date: 28/10/2026 Place: Surat Pradeep Kumar Singhi (Partner) M. No. 200/024612 UDIN: 26024612IMDZZB7149 A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001 PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com zt a A O ZOTAH EAlllt CARE UMITED .... @U nauditeSdta ndalFoinnea nRciesultsa forl the quarteern d30the dSe ptember, 2026 (mAo utn,, ·nLa khs ,exptce pe rsh a read ta) QuarteErn ded HaYlfe aErn ded YeaErn ded Particulars 30-09-2026 30-06-2026 30-09-2025 30-09-2026 30-09-2025 31-03-2026 (Unaudited) (Unaudit(eUdn)a udited) (UnauIdi t(eUdn audited()A udited) I. Revenfureo Omp erations 12606.54 12702.91 9942.42 25309.451 7743.1420 700.72 II. OthIenrc ome 389.50 394.26 326.71 783.76 550.10 1340.18 Ill.To talI ncome 12996.04 13097.17 10269.132 6093.21 18293.2422 040.91 IV. Expenses: CosotfM aterCioanlssu med 154.99 236.97 288.85 391.97 779.38 1746.43 PurchoafSs teosc k-in-Trade 8996.71 7704.85 4810.83 16701.56 8253.042 3674.65 ChangienIs n ventoofFr iineisGs ohoeddWs o,r k-in-aPnrdo gress 0.00 Stock-in-Trade (1210.24()8 30.13) 336.39 (2040.37)8 73.29( 2550.99) EmploByeeneeE fxitp enses 1634.33 1238.95 1025.36 2873.28 2022.944 889.32 FinaCnocset s 55.76 29.86 8.67 85.62 12.35 25.26 Deprec/iA amtoirotnia snaDdte ipolneE txipoenn se 143.97 126.88 91.04 270.86 170.72 395.43 OthEexrp enses 3081.43 4329.54 2400.92 7410.97 4019.899 785.45 TotaElx penses 12856.96 12836.92 8962.07 25693.88 16131.6317 965.54 V. ProbfefiotrE exc eptiitoeanmnastdl a f xr ocmo ntionpueirnagt ions (Ill-IV) 139.07 260.25 1307.05 399.32 2161.614 075.36 VI. ExcepIttieomnsa l - - (98.96) VII.P rofitb/e(fltooarsxes ) 139.07 260.25 1307.05 399.32 2161.613 976.40 VIIIT.a Exx pense: (1 )C urrteanxt 28.03 75.99 332.17 104.01 555.85 1095.36 - - - - (1.I1.&)TD .DT aPxr ovisioSnh oCerrxt/ec aetsesd (1.905) (2D)e feTrarxe d 1.19 5.46 15.97 6.65 (24.47)( 101.34) IX. Pro(fLiotfs/os tr)h p ee rfiroodCm o ntinuing Opera(tViIoIn-sV III) 112.24 189.72 990.85 301.96 1581.292 790.66 X. Profit/(bleofstosarf)xer odmi sconotpienruaetdi ons XI. TaExx peonfds ies conOtpienruaetdi ons XII.P ro(fLiotfs/rs oD)mi sconOtpienruae(tdai foTtnaesxr ) (X-XI) XIIIP.r ofit/ (Loss)fo rth epe riod 112.24 189.72 990.85 301.96 1581.292 790.66 XIV.Oth erC ompreheInnsciovmee A (iI)t etmhswa itnl olbt er eclatsosS itfaiteeodmf e nt proafnitld o ss 12.66 (34.60) (21). 94 (16.09)5 0.81 (iIin)c oTmarexe lattoii tnetgmh swa itnl olbt e reclatsoSs tifaiteedom pfer notaf nildto ss (3.19) 8.71 5.52 4.05 (12.79) B( iI)t etmhswa itbl erl e clatsoSs tifaiteedom fpe rnotf it anldo ss - - - - - (iIin)c oTmarexe lattoii tnegtm hswa itbl erl ec lassified top roafnildto ss - - - - - (iiiv)aFlcauhiear n ognies n vestnmeetn ts, Othceorm prehienncsofimovtereh pee rinoeodtft, a x 9.47 (25.90) (16.42) (1.204) 38.02 Totaclo mprehienncsofoimrvthe ee pe ri(XodI +IX IIV) 12L71 163.82 990.85 285.54 156.924 2828.68 PaidE-quupSi htayCr aep ital 3463.26 3463.26 3064.38 3463.26 3064.383 463.26 OthEeqru ity 85356.94 Earnpienergq su sihtayor ffe a vcaeel o uf1f0 each (1 )B as(irfc/\) 0.32 0.55 3.27 0.87 5.30 8.48 (2D.)i lutefd--)( in 0.32 0.55 3.12 0.87 5.05 8.48 denoftiegsul reteshssaa ln a kh Foarn odn be haolfthf e Bo ard FoPrr adKe.Se ipn &gA hsis ociates CharterAecdc ountants FirNmo0 .1 26027W th::� Director�)) HimanMs.Zh otau MoxeKs.Zotah (D:i0 n1 097722) (Di:0 n7 625219) PradKeuempaS rl nghi (Partner) .'-M.N o2.00 /024612 CompaSencyr etary GroCuEpO AshvVianr iya SujitPaul Date2:8 -10-2026 Pla:cS eu [Showing first 8,000 characters — download PDF for full document]